chufangao/CTO huggingface dataset:
Clinical trial NCT02047513: Neoadjuvant Plus Adjuvant or Only Adjuvant Nab- Paclitaxel Plus Gemcitabine for Resectable Pancreatic Cancer
Official title: Neoadjuvant Plus Adjuvant or Only Adjuvant Nab-Paclitaxel Plus Gemcitabine for Resectable Pancreatic Cancer: A Prospective, Randomized, Controlled, Phase II Study of the AIO (Working Group for Medical Oncology From the German Cancer Society) Pancreatic Cancer Group
Acronym: NEONAX
Sponsor: AIO-Studien-gGmbH (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: COMPLETED 
Enrollment: 127.0 (ACTUAL)
Number of arms: 2.0
Start date: 2015-07-31
Primary completion date: 2021-04-30
Completion date: 2022-10-31
Clinical trial NCT02578641: A Phase III Trial Evaluating Chemotherapy and Immunotherapy for Advanced Nasopharyngeal Carcinoma (NPC) Patients
Official title: A Multicentre, Randomized, Open-Label, Phase III Clinical Trial Of Gemcitabine And Carboplatin Followed By Epstein-Barr Virus-Specific Autologous Cytotoxic T Lymphocytes Versus Gemcitabine And Carboplatin As First Line Treatment For Advanced Nasopharyngeal Carcinoma(NPC) Patients
Acronym: VANCE
Sponsor: Tessa Therapeutics (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: COMPLETED 
Enrollment: 330.0 (ACTUAL)
Number of arms: 2.0
Start date: 2014-07-31
Primary completion date: 2022-02-28
Completion date: 2022-02-28
Baseline population: Intent-to-treat Analysis Set - all subjects randomized to treatment.
Clinical trial NCT03330197: A Study of Ad-RTS-hIL-12 + Veledimex in Pediatric Subjects With Brain Tumors Including DIPG
Official title: A Phase I/II Study of Ad-RTS-hIL-12, an Inducible Adenoviral Vector Engineered to Express hIL-12 in the Presence of the Activator Ligand Veledimex in Pediatric Brain Tumor Subjects
Sponsor: Alaunos Therapeutics (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE1/PHASE2
Status: TERMINATED 
Why stopped: Sponsor decision due to slow accrual
Enrollment: 6.0 (ACTUAL)
Number of arms: 2.0
Start date: 2017-09-26
Primary completion date: 2021-09-10
Completion date: 2021-09-10
Plan to share individual participant data: UNDECIDED
Clinical trial NCT03332589: E6201 Plus Dabrafenib for the Treatment of Metastatic Melanoma Central Nervous System Metastases (CNS)
Official title: A Phase 1 Study of E6201 Plus Dabrafenib for the Treatment of Central Nervous System Metastases (CNS) From BRAF V600-Mutated Metastatic Melanoma
Sponsor: Spirita Oncology, LLC (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: TERMINATED 
Why stopped: Single center study: Principal Investigator left institution.
Enrollment: 4.0 (ACTUAL)
Number of arms: 3.0
Start date: 2018-07-02
Primary completion date: 2021-04-30
Completion date: 2021-10-11
Baseline population: No subjects were enrolled in the Combination Safety Run-In or Expansion Phases of the study.
Limitations and caveats: Due to the departure of the study PI from the institution, the study was terminated early.
Plan to share individual participant data: NO
Clinical trial NCT05525156: The Effect of Aspirin on HIV Disease Progression Among HIV- Infected Individuals Initiating Anti- Retroviral Therapy
Official title: The Effect of Aspirin on HIV Disease Progression Among HIV- Infected Individuals Initiating Anti- Retroviral Therapy
Sponsor: Muhimbili University of Health and Allied Sciences (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: SUSPENDED 
Why stopped: The study stopped due to expiry of study drugs
Enrollment: 454.0 (ESTIMATED)
Number of arms: 2.0
Start date: 2020-03-02
Primary completion date: 2022-06-22
Completion date: 2023-06-22
Plan to share individual participant data: YES
IPD sharing description: Individual participant data that underlie the results reported in the respective article, after deidentification (text, tables, figures and appendices).
IPD time frame: From 9 months and to 36 months after article publication
IPD access criteria: Investigators with approval by an independent review committee for proposed use of data. Data will be shared for individual participant data meta analysis The mechanism by which data will be made available is that proposals may be submitted up to 36 months after respective article publication. after this period data will be made available at MUHAS data warehouse but without investigator support other than deposited metadata.
Clinical trial NCT04609397: A Study to Evaluate the Efficacy and Safety of Hemay005 in the Treatment of Behçet Disease
Official title: A Phase Ⅱ Study to Evaluate the Efficacy and Safety of Hemay005 in the Treatment of Behçet Disease
Sponsor: Ganzhou Hemay Pharmaceutical Co., Ltd (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: TERMINATED 
Why stopped: The study purpose has been achieved
Enrollment: 89.0 (ACTUAL)
Number of arms: 3.0
Start date: 2020-11-30
Primary completion date: 2022-04-30
Completion date: 2022-04-30
Plan to share individual participant data: NO
Clinical trial NCT04031833: Encochleated Oral Amphotericin for Cryptococcal Meningitis Trial (EnACT)
Official title: Encochleated Oral Amphotericin for Cryptococcal Meningitis Trial
Acronym: EnACT
Sponsor: Matinas BioPharma Nanotechnologies, Inc. (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE1/PHASE2
Status: COMPLETED 
Enrollment: 178.0 (ACTUAL)
Number of arms: 3.0
Start date: 2019-10-24
Primary completion date: 2022-11-14
Completion date: 2023-02-15
Plan to share individual participant data: NO
Clinical trial NCT04130399: Study of Neoadjuvent Chemotherapy Followed by SBRT in Patients With Resectable and Borderline Resectable Pancreatic Cancer
Official title: Study of Neoadjuvent Chemotherapy Followed by SBRT in Patients With Resectable and Borderline Resectable Pancreatic Cancer
Sponsor: Indiana University (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: WITHDRAWN 
Why stopped: Study is being abandoned.
Enrollment: 0.0 (ACTUAL)
Number of arms: 1.0
Start date: 2019-07-01
Primary completion date: 2022-01-01
Completion date: 2023-01-01
Clinical trial NCT05698888: Study of VP301 in Patients With Multiple Myeloma, Lymphoma, or Solid Tumors
Official title: A Phase 1 Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of VP301 in Patients With Relapsed or Refractory Multiple Myeloma, Lymphoma, or Solid Tumors
Sponsor: Virtuoso BINco, Inc. (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: TERMINATED 
Why stopped: Sponsor Decision
Enrollment: 2.0 (ACTUAL)
Number of arms: 2.0
Start date: 2022-11-29
Primary completion date: 2023-06-19
Completion date: 2023-06-19
Plan to share individual participant data: NO
Clinical trial NCT04728347: Open Label Extension Study to Assess the Safety and Long-Term Immunogenicity of ARCT-021
Official title: A Phase 2a, Open Label Extension Study to Assess the Safety and Long-Term Immunogenicity of ARCT-021
Sponsor: Arcturus Therapeutics, Inc. (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: TERMINATED 
Why stopped: A decision was made to terminate the study for operational/business reasons. This study was not terminated for reasons of safety or immunogenicity.
Enrollment: 65.0 (ACTUAL)
Number of arms: 2.0
Start date: 2021-01-04
Primary completion date: 2021-12-28
Completion date: 2021-12-28
Plan to share individual participant data: NO
Clinical trial NCT04620733: RESPONSE: Response to Seladelpar in Subjects With Primary Biliary Cholangitis (PBC) and an Inadequate Control to or an Intolerance to Ursodeoxycholic Acid (UDCA)
Official title: RESPONSE: A Placebo-controlled, Randomized, Phase 3 Study to Evaluate the Efficacy and Safety of Seladelpar in Patients With Primary Biliary Cholangitis (PBC) and an Inadequate Response to or an Intolerance to Ursodeoxycholic Acid (UDCA)
Sponsor: Gilead Sciences (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: COMPLETED 
Enrollment: 193.0 (ACTUAL)
Number of arms: 2.0
Start date: 2021-04-21
Primary completion date: 2023-08-11
Completion date: 2023-08-11
Baseline population: The Safety Analysis Set was defined as any participant who received at least 1 dose of study drug.
Clinical trial NCT04520620: Concentration-effect Relationship of Enoxaparin for Thromboembolic Prevention
Official title: Evaluation of the Concentration-effect Relationship of Enoxaparin for Thromboembolic Prevention in COVID-19 Intensive Unit Care Patients.
Acronym: COV-ENOX
Sponsor: Centre Hospitalier Universitaire de Saint Etienne (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE4
Status: WITHDRAWN 
Why stopped: End of the COVID 19 epidemic in the region and decision to participate in a national study on the same subject (COVI-DOSE).
Enrollment: 0.0 (ACTUAL)
Number of arms: 1.0
Start date: 2020-05-02
Primary completion date: 2020-07-10
Completion date: 2020-07-10
Plan to share individual participant data: NO
Clinical trial NCT02285062: Efficacy and Safety Study of Lenalidomide Plus R-CHOP Chemotherapy Versus Placebo Plus R-CHOP Chemotherapy in Untreated ABC Type Diffuse Large B-cell Lymphoma
Official title: Phase 3 Randomized, Double-Blind, Placebo Controlled, Multicenter Study to Compare the Efficacy and Safety of Lenalidomide (CC-5013) Plus R-CHOP Chemotherapy (R2-CHOP) Versus Placebo Plus R-CHOP Chemotherapy in Subjects With Previously Untreated Activated B-cell Type Diffuse Large B-cell Lymphoma
Acronym: ROBUST
Sponsor: Celgene (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: COMPLETED 
Enrollment: 570.0 (ACTUAL)
Number of arms: 2.0
Start date: 2015-02-17
Primary completion date: 2019-03-15
Completion date: 2022-07-28
Baseline population: The Intent-to-treat (ITT) population was defined as all participants who were randomized into the trial, regardless of whether they received study treatment or not.
Clinical trial NCT02164578: Microvascular and Antiinflammatory Effects of Rivaroxaban Compared to Aspirin in Type-2 Diabetic Patients With Subclinical Inflammation and High Cardiovascular Risk
Official title: Microvascular and Antiinflammatory Effects of Rivaroxaban Compared to Low Dose Aspirin in Type-2 Diabetic Patients With Very High Cardiovascular Risk and Subclinical Inflammation
Acronym: MicroVasc-DIVA
Sponsor: GWT-TUD GmbH (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: COMPLETED 
Enrollment: 179.0 (ACTUAL)
Number of arms: 2.0
Start date: 2015-04-30
Primary completion date: 2018-12-12
Completion date: 2020-04-30
Baseline population: Baseline characteristics were assessed for the full analysis set (n=179)
Clinical trial NCT02261519: Study to Evaluate Safety & Efficacy of NaBen® as Add-on Treatment for Schizophrenia in Adults
Official title: An Adaptive, Phase IIb/III, Multi-center, Prospective, Randomized, Double-Blind Placebo-controlled Study of the Safety and Efficacy of NaBen® (DAAO Inhibitor), as an Add-on Treatment for Schizophrenia in Adults
Sponsor: SyneuRx International (Taiwan) Corp (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE2/PHASE3
Status: TERMINATED 
Why stopped: due to commercial strategy
Enrollment: 280.0 (ACTUAL)
Number of arms: 2.0
Start date: 2017-03-29
Primary completion date: 2023-11-29
Completion date: 2023-11-29
Clinical trial NCT04958434: Study of TST005 in Patients With Locally Advanced or Metastatic Solid Tumors
Official title: A Phase 1, First in Human, Open-label, Dose Escalation and Dose Expansion Study of TST005 in Patients With Locally Advanced or Metastatic Solid Tumors
Sponsor: Suzhou Transcenta Therapeutics Co., Ltd. (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: TERMINATED 
Why stopped: Corporate Decision
Enrollment: 19.0 (ACTUAL)
Number of arms: 2.0
Start date: 2021-06-11
Primary completion date: 2023-09-30
Completion date: 2023-09-30
Plan to share individual participant data: NO
IPD sharing description: individual participant data (IPD) will not be shared to other researchers
Clinical trial NCT03537534: Intraurethral Lidocaine After Endourology Procedures
Official title: Intraurethral Lidocaine After Endourology Procedure to Improve Dysuria in Anesthetized Patients
Sponsor: San Antonio Uniformed Services Health Education Consortium (FED)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: TERMINATED 
Why stopped: Lack of enrollment
Enrollment: 35.0 (ACTUAL)
Number of arms: 2.0
Start date: 2018-04-15
Primary completion date: 2022-09-01
Completion date: 2022-09-01
Plan to share individual participant data: NO
Clinical trial NCT03522844: Treatments for Anxiety: Meditation and Escitalopram
Official title: Comparative Effectiveness of Mindfulness-Based Stress Reduction and Pharmacotherapy for Anxiety
Acronym: TAME
Sponsor: Georgetown University (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE4
Status: COMPLETED 
Enrollment: 276.0 (ACTUAL)
Number of arms: 2.0
Start date: 2018-06-18
Primary completion date: 2021-10-31
Completion date: 2022-01-05
Plan to share individual participant data: NO
Clinical trial NCT02854436: An Efficacy and Safety Study of Niraparib in Men With Metastatic Castration-Resistant Prostate Cancer and DNA-Repair Anomalies
Official title: A Phase 2 Efficacy and Safety Study of Niraparib in Men With Metastatic Castration-Resistant Prostate Cancer and DNA-Repair Anomalies
Acronym: Galahad
Sponsor: Janssen Research & Development, LLC (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: COMPLETED 
Enrollment: 289.0 (ACTUAL)
Number of arms: 1.0
Start date: 2016-08-31
Primary completion date: 2021-01-26
Completion date: 2023-08-16
Clinical trial NCT03994926: Evaluation of an Eye Tracking Sensor to Detect Cannabis Impairment
Official title: Evaluation of an Eye Tracking Sensor to Detect Cannabis Impairment
Sponsor: Battelle Memorial Institute (OTHER)
Study type: INTERVENTIONAL
Phase: EARLY_PHASE1
Status: TERMINATED 
Why stopped: COVID-19 Pandmic halted study
Enrollment: 3.0 (ACTUAL)
Number of arms: 1.0
Start date: 2020-02-03
Primary completion date: 2020-03-13
Completion date: 2020-03-13
Plan to share individual participant data: NO
Clinical trial NCT03450018: A Study of SLC-0111 and Gemcitabine for Metastatic Pancreatic Ductal Cancer in Subjects Positive for CAIX
Official title: An Open-label, Multi-center, Phase 1b Study to Investigate the Safety and Tolerability of SLC-0111 (WBI-5111) in Combination With Gemcitabine in Metastatic Pancreatic Ductal Adenocarcinoma Subjects Positive for Carbonic Anhydrase IX
Acronym: SLC-0111-17-01
Sponsor: British Columbia Cancer Agency (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE1/PHASE2
Status: TERMINATED 
Why stopped: Changing treatment landscape: The availability of nab-paclitaxel with gemcitabine in the second-line setting has changed the feasibility of further recruitment and potential long-term development opportunities of SLC-0111 with gemcitabine alone.
Enrollment: 6.0 (ACTUAL)
Number of arms: 1.0
Start date: 2019-01-10
Primary completion date: 2024-05-16
Completion date: 2024-05-16
Plan to share individual participant data: NO
Clinical trial NCT03777657: Tislelizumab in Combination With Chemotherapy as First-Line Treatment in Adults With Inoperable, Locally Advanced or Metastatic Gastric, or Gastroesophageal Junction Carcinoma
Official title: A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Clinical Study Comparing the Efficacy and Safety of Tislelizumab (BGB-A317) Plus Platinum and Fluoropyrimidine Versus Placebo Plus Platinum and Fluoropyrimidine as First-Line Treatment in Patients With Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma
Sponsor: BeiGene (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: COMPLETED 
Enrollment: 997.0 (ACTUAL)
Number of arms: 2.0
Start date: 2018-12-13
Primary completion date: 2023-02-28
Completion date: 2024-08-27
Plan to share individual participant data: YES
Clinical trial NCT03394287: A Trial of SHR-1210 (an Anti-PD-1 Antibody) in Combination With Apatinib in Patients With Advanced TNBC
Official title: A Phase II, Open-labeled, Randomised, Non-comparative, Two-arms Investigator-initiated Clinical Trial of SHR-1210 (Anti-PD-1 Antibody) in Combination With Apatinib in Subjects With Advanced Triple Negative Breast Cancer
Sponsor: Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: COMPLETED 
Enrollment: 40.0 (ACTUAL)
Number of arms: 2.0
Start date: 2018-01-10
Primary completion date: 2019-12-30
Completion date: 2020-09-30
Plan to share individual participant data: UNDECIDED
Clinical trial NCT04037527: Gemcitabine and Docetaxel With Radiation in Adults With Soft Tissue Sarcoma of the Extremities
Official title: Phase I Trial Study of Gemcitabine and Docetaxel With Radiation in Adult Patients With High Grade and Greater Than 5 cm Soft Tissue Sarcoma of the Extremities
Sponsor: Wake Forest University Health Sciences (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: SUSPENDED 
Why stopped: Per the PI, this study is on hold to accrual pending an amendment that will need to be submitted to the IRB.
Enrollment: 27.0 (ESTIMATED)
Number of arms: 1.0
Start date: 2020-08-18
Primary completion date: 2024-09-30
Completion date: 2024-09-30
Plan to share individual participant data: NO
Clinical trial NCT03953209: Spironolactone for the Treatment of Melasma
Official title: Spironolactone for the Treatment of Melasma: a Prospective, Open-label Proof-of-concept and Dose-ranging Study
Sponsor: Medical University of South Carolina (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: WITHDRAWN 
Why stopped: Conflict with funding
Enrollment: 0.0 (ACTUAL)
Number of arms: 3.0
Start date: 2020-03-05
Primary completion date: 2021-01-01
Completion date: 2021-01-01
Plan to share individual participant data: NO
Clinical trial NCT03386344: Efficacy and Bone Safety of Sotagliflozin 400 and 200 mg Versus Placebo in Participants With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control
Official title: A 26-week Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter, Phase 3 Study With a 78-week Extension Period to Evaluate the Efficacy and Bone Safety of Sotagliflozin in Patients 55 Years or Older With Type 2 Diabetes Mellitus and Inadequate Glycemic Control
Acronym: SOTA-BONE
Sponsor: Lexicon Pharmaceuticals (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: TERMINATED 
Why stopped: Study terminated prematurely for financial reasons and Covid-19 pandemic.
Enrollment: 376.0 (ACTUAL)
Number of arms: 3.0
Start date: 2018-02-19
Primary completion date: 2019-05-22
Completion date: 2020-05-30
Baseline population: The randomized population included any participant who had been allocated to a randomized treatment regardless of whether the treatment kit was used.
Plan to share individual participant data: NO
Clinical trial NCT04263142: A Relative Bioavailability and Food-Effect Study of GSK3640254 Tablet and Capsule Formulations in Healthy Participants
Official title: A Two-Part, Randomized, Open-Label, Single Dose, Crossover Clinical Trial to Assess the Relative Bioavailability of a Tablet Compared to a Capsule of GSK3640254 and to Assess the Effect of Food on the GSK3640254 Tablet in Healthy Participants
Sponsor: ViiV Healthcare (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: COMPLETED 
Enrollment: 39.0 (ACTUAL)
Number of arms: 5.0
Start date: 2020-01-27
Primary completion date: 2020-03-24
Completion date: 2020-03-24
Plan to share individual participant data: YES
IPD sharing description: IPD for this study will be made available via the Clinical Study Data Request site.
IPD time frame: IPD will be made available within 6 months of publishing the results of the primary endpoints of the study.
IPD access criteria: Access is provided after a research proposal is submitted and has received approval from the Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months but an extension can be granted, when justified, for up to another 12 months.
Clinical trial NCT03573986: Pilot Study of 18F-FMISO PET/CT and MRI Imaging to Explore Tissue Hypoxia and Arteriovenous Shunting in Subjects With Recurrent Glioblastoma Before and After Bevacizumab Treatment
Official title: Pilot Study of 18F-FMISO PET/CT and MRI Imaging to Explore Tissue Hypoxia and Arteriovenous Shunting in Subjects With Recurrent Glioblastoma Before and After Bevacizumab Treatment
Sponsor: Abramson Cancer Center at Penn Medicine (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: TERMINATED 
Why stopped: Lack of enrollment
Enrollment: 2.0 (ACTUAL)
Number of arms: 1.0
Start date: 2018-04-18
Primary completion date: 2020-01-14
Completion date: 2020-01-14
Clinical trial NCT03240393: Study of Oral cMET Inhibitor INC280 in Chinese Patients With EGFR Wild-type Advanced Non-small Cell Lung Cancer (NSCLC)
Official title: Phase II Multicenter 3-cohort Study of Oral cMET Inhibitor INC280 in Chinese Patients With EGFR Wild-type Advanced Non-small Cell Lung Cancer (NSCLC) Who Have Received 1 or 2 Prior Lines of Systemic Therapy for Advanced/Metastatic Disease
Sponsor: Novartis (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: WITHDRAWN 
Why stopped: Company Decision
Enrollment: 0.0 (ACTUAL)
Number of arms: 3.0
Start date: 2018-07-31
Primary completion date: 2021-10-26
Completion date: 2021-10-26
Plan to share individual participant data: UNDECIDED
IPD sharing description: Planned Shared Data Description: Copy and paste this Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations.~This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com
Clinical trial NCT03608774: Trial of Azithromycin vs. Doxycycline for the Treatment of Rectal Chlamydia in MSM
Official title: A Phase 4, Randomized, Double-Blinded, Placebo-Controlled Trial of Azithromycin Versus Doxycycline for the Treatment of Rectal Chlamydia in Men Who Have Sex With Men
Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) (NIH)
Study type: INTERVENTIONAL
Phase: PHASE4
Status: COMPLETED 
Enrollment: 177.0 (ACTUAL)
Number of arms: 2.0
Start date: 2018-07-13
Primary completion date: 2020-02-21
Completion date: 2020-02-21
Baseline population: All randomized subjects, receiving or not receiving the study product, are included in the baseline analysis population.
Clinical trial NCT04421456: Trial to Investigate the Safety and Efficacy of GWP42003-P Versus Placebo as Adjunctive Therapy in Participants With Schizophrenia Experiencing Inadequate Response to Ongoing Antipsychotic Treatment
Official title: A Randomized, Double-blind, Parallel-group Trial to Investigate the Safety and Efficacy of GWP42003-P Versus Placebo as Adjunctive Therapy in Participants With Schizophrenia Experiencing Inadequate Response to Ongoing Antipsychotic Treatment
Sponsor: Jazz Pharmaceuticals (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: TERMINATED 
Why stopped: This study was terminated based on a business decision by the Sponsor.
Enrollment: 95.0 (ACTUAL)
Number of arms: 3.0
Start date: 2020-08-18
Primary completion date: 2022-03-16
Completion date: 2022-03-16
Baseline population: Demographics and baseline characteristics were assessed in the Full Analysis Set in the Treatment Period.
Plan to share individual participant data: NO
Clinical trial NCT04547101: A Study of AK104 in Subjects With Locally Advanced Unresectable or Metastatic MSI-H/dMMR Solid Tumors
Official title: A Single-arm, Open-label, Multicenter, Phase II Study of AK104, a PD-1/CTLA-4 Bispecific Antibody, in Subjects With Locally Advanced Unresectable or Metastatic Microsatellite Instability-High (MSI-H) or Mismatch Repair Deficient (dMMR) Solid Tumors
Sponsor: Akeso (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: TERMINATED 
Why stopped: Due to difficuty of erollment and consideration of clinical guideline,The sponsor decided to stop study.
Enrollment: 6.0 (ACTUAL)
Number of arms: 1.0
Start date: 2020-04-24
Primary completion date: 2022-09-30
Completion date: 2022-09-30
Plan to share individual participant data: NO